NASDAQ : ARWR
Arrowhead Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 59.9 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 8.46B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 8.46B |
| Enterprise Value | 8.24B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 24, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 141.25M |
| Shares Outstanding | 141.25M |
| Shares Change (YoY) | +7.74% |
| Shares Change (QoQ) | +0.67% |
| Owned by Insiders (%) | 3.32% |
| Owned by Institutions (%) | 77.74% |
| Float | 122.45M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.64 |
| Forward PS | 41.31 |
| PB Ratio | 18.16 |
| P/TBV Ratio | 18.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 12.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.90 |
| Quick Ratio | 5.71 |
| Debt / Equity | 2.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.45 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -55.21% |
| Return on Assets (ROA) | -8.10% |
| Return on Invested Capital (ROIC) | -101.07% |
| Return on Capital Employed (ROCE) | -12.38% |
| Weighted Average Cost of Capital (WACC) | 10.56% |
| Revenue Per Employee | $941,624 |
| Profits Per Employee | -$450,007 |
| Employee Count | 711 |
| Asset Turnover | 0.38 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 20.05M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.30 |
| 52-Week Price Change | +48.67% |
| 50-Day Moving Average | 69.79 |
| 200-Day Moving Average | 71.73 |
| Relative Strength Index (RSI) | 40.88 |
| Average Volume (20 Days) | 1,755,601 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.96M |
| Short Previous Month | 10.76M |
| Short % of Shares Out | 7.76% |
| Short % of Float | 8.95% |
| Short Ratio (days to cover) | 4.41 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 669.50M |
| Gross Profit | 669.50M |
| Operating Income | -226.44M |
| Pretax Income | -252.08M |
| Net Income | -319.96M |
| EBITDA | -200.64M |
| EBIT | -226.44M |
| Loss Per Share | -$2.28 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.60B |
| Total Debt | 1.38B |
| Net Cash | 218.46M |
| Net Cash Per Share | $1.55 |
| Equity (Book Value) | 466.04M |
| Book Value Per Share | 3.30 |
| Working Capital | 1.39B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -59.06M |
| Capital Expenditures | -16.06M |
| Depreciation & Amortization | 25.80M |
| Net Borrowing | 585.27M |
| Free Cash Flow | -75.11M |
| FCF Per Share | -$0.53 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -33.82% |
| Pretax Margin | -37.65% |
| Profit Margin | -47.79% |
| EBITDA Margin | -29.97% |
| EBIT Margin | -33.82% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.74% |
| Shareholder Yield | -7.74% |
| Earnings Yield | -3.81% |
| FCF Yield | -0.89% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $107.71 |
| Price Target Difference | 79.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | -8.84% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 17, 2011 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.1 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |